Petmal/iStock via Getty Images Thesis Plug Power Inc. ( PLUG ) is building a fully integrated green hydrogen business . This includes making PEM electrolyzers to produce hydrogen, liquefying the hydrogen, transporting it, and providing fuel cell power systems that use it. When I last covered PLUG , I gave it a Hold rating. While the long-term potential of the hydrogen market looked attractive, the...
Petmal/iStock via Getty Images Thesis Plug Power Inc. ( PLUG ) is building a fully integrated green hydrogen business . This includes making PEM electrolyzers to produce hydrogen, liquefying the hydrogen, transporting it, and providing fuel cell power systems that use it. When I last covered PLUG , I gave it a Hold rating. While the long-term potential of the hydrogen market looked attractive, the company's ongoing losses and continued cash burn really made it difficult for me to justify the stock's valuation at that time. Seeking Alpha PLUG did have a nice surge in share price last fall. Unfortunately, not considering today's ~10% pre-market pop, that momentum has been running out of steam. All the same, after reviewing the company's latest results, I'm maintaining my neutral stance. The operational progress is encouraging but not yet strong enough to fully offset the structural and financial risks still hanging over the company. Plug Power Q4 2025: My Perspective Seeking Alpha Q4 2025 gross margin : +2.4% (vs. -122.5% in Q4 2024) Gross margin improvement: +125 percentage points YoY FY 2025 revenue growth: ~13% Q4 2025 revenue: $225.22 million (+17.63% YoY). Plug Power was finally able to make a profit on its basic sales (positive gross margins) after spending years investing money. It lowered the cost of servicing each unit, improved how efficiently its hydrogen production sites started operating, including the Louisiana facility , and benefited from selling more products. Essentially, when sales went up, the company just spread the same fixed costs like rent, admin expenses, maybe executive coffee budget, across a larger pile, so to speak. As for the backdrop, it now points to wider policy support kicking in. Europe's RED III rules are translating into national laws. For example, Italy, where I'm currently situated, has recently written these rules into its national legislation. This is helping speed up efforts to cut pollution from oil refineries and to develop ...
"We understand how deeply distressing and concerning this incident is and we will have extra officers in the area to offer reassurance to the community," Det Supt James Munro said.
"We understand how deeply distressing and concerning this incident is and we will have extra officers in the area to offer reassurance to the community," Det Supt James Munro said.
Amazon.comAMZN made a significant move to deepen its AI footprint recently, announcing a multi-year strategic partnership with OpenAI alongside a commitment to invest up to $50 billion in the ChatGPT-maker. The initial tranche of $15 billion will be followed by an additional $35 billion contingent on certain conditions being met. The announcement comes just weeks after Amazon reported its fourth-q...
Amazon.comAMZN made a significant move to deepen its AI footprint recently, announcing a multi-year strategic partnership with OpenAI alongside a commitment to invest up to $50 billion in the ChatGPT-maker. The initial tranche of $15 billion will be followed by an additional $35 billion contingent on certain conditions being met. The announcement comes just weeks after Amazon reported its fourth-quarter 2025 results, positioning the deal as a direct extension of the company's AI-first strategy. The partnership is structured around several interconnected pillars. Amazon Web Services (“AWS”) and OpenAI will co-create a Stateful Runtime Environment powered by OpenAI models, available on Amazon Bedrock, and AWS will serve as the exclusive third-party cloud distribution provider for OpenAI Frontier, the latter's enterprise agent platform. Additionally, OpenAI will consume 2 gigawatts of Trainium capacity through AWS infrastructure and will expand its existing compute agreement with AWS by $100 billion over the next eight years. The companies also plan to develop customized models for Amazon's consumer-facing applications. The timing is strategically significant. In the fourth quarter of 2025, AWS revenues grew 24% year over year to $35.6 billion — the fastest growth rate in 13 quarters — with an annualized run rate of $142 billion and an AWS backlog of $244 billion, up 40% year over year. Yet the deal introduces risk alongside opportunity. Amazon has guided for approximately $200 billion in capital expenditures in 2026, and the OpenAI investment adds to an already elevated capital commitment. The $35 billion portion of the investment remains contingent, and the underlying joint collaboration agreement has not been made public, leaving key termination terms undisclosed. Free cash flow fell sharply to $11.2 billion on a trailing 12-month basis despite a 20% rise in operating cash flow, underscoring the tension between long-term AI positioning and near-term financial flexib...
Image source: The Motley Fool. Tuesday, March 3, 2026 at 8 a.m. ET Call participants Co-Chief Executive Officer — Justin B. Klee Co-Chief Executive Officer — Joshua B. Cohen Chief Medical Officer — Dr. Camille L. Bedrosian Chief Financial Officer — James M. Frates Need a quote from a Motley Fool analyst? Email [email protected] Takeaways Cash and marketable securities -- $317 million at quarter-en...
Image source: The Motley Fool. Tuesday, March 3, 2026 at 8 a.m. ET Call participants Co-Chief Executive Officer — Justin B. Klee Co-Chief Executive Officer — Joshua B. Cohen Chief Medical Officer — Dr. Camille L. Bedrosian Chief Financial Officer — James M. Frates Need a quote from a Motley Fool analyst? Email [email protected] Takeaways Cash and marketable securities -- $317 million at quarter-end, representing a decrease from $344 million at the end of the prior quarter. -- $317 million at quarter-end, representing a decrease from $344 million at the end of the prior quarter. Anticipated cash runway -- Management expects funding to last into 2028, supporting operations through LUCIDITY top-line data, potential FDA approval, and a possible commercial launch of Avexatide in 2027. -- Management expects funding to last into 2028, supporting operations through LUCIDITY top-line data, potential FDA approval, and a possible commercial launch of Avexatide in 2027. Total operating expenses -- $36.6 million for the quarter, an 8% decline compared to the same period in 2024. -- $36.6 million for the quarter, an 8% decline compared to the same period in 2024. Research and development expenses -- $21.2 million, lower than $22.9 million in the comparable prior-year quarter, attributed to reduced spending on AMX035 and offset by increased Avexatide development costs. -- $21.2 million, lower than $22.9 million in the comparable prior-year quarter, attributed to reduced spending on AMX035 and offset by increased Avexatide development costs. Selling, general, and administrative expenses -- $15.4 million versus $17.1 million in Q4 2024, reflecting reduced consulting and professional service costs. -- $15.4 million versus $17.1 million in Q4 2024, reflecting reduced consulting and professional service costs. Non-cash stock-based compensation -- $6.4 million for the quarter, down from $6.8 million in Q4 2024. -- $6.4 million for the quarter, down from $6.8 million in Q4 2024. Mileston...
Amazon.com Inc has said two Amazon Web Services data centres in the United Arab Emirates were hit by drone strikes, with another facility in Bahrain damaged by a nearby attack, as Iran retaliated to the strikes by the US and Israel. Joint US and Israeli strikes on Iran started over the...
Amazon.com Inc has said two Amazon Web Services data centres in the United Arab Emirates were hit by drone strikes, with another facility in Bahrain damaged by a nearby attack, as Iran retaliated to the strikes by the US and Israel. Joint US and Israeli strikes on Iran started over the...
Kontoor Brands (NYSE:KNG) delivered a clean double beat to open fiscal 2026, reporting Q4 2025 adjusted EPS of $1.73 against a consensus estimate of $1.67, a +4.85% positive surprise. Revenue came in at $1.018 billion, clearing the $988.8 million estimate by nearly $29 million. Shares were trading at $64.82 heading into today’s session, up 6.11% ... Kontoor Crosses $1B Revenue Mark as Profitabilit...
Kontoor Brands (NYSE:KNG) delivered a clean double beat to open fiscal 2026, reporting Q4 2025 adjusted EPS of $1.73 against a consensus estimate of $1.67, a +4.85% positive surprise. Revenue came in at $1.018 billion, clearing the $988.8 million estimate by nearly $29 million. Shares were trading at $64.82 heading into today’s session, up 6.11% ... Kontoor Crosses $1B Revenue Mark as Profitability Slips
Poland’s state-run fertilizer producer has temporarily stopped taking new orders as tensions soar in the Middle East and the price of gas, a key input, surges. Grupa Azoty SA will continue production, and the decision applies only to new March orders for nitrogen fertilizers, the company said in a statement. “The reason for the decision is the unstable geopolitical situation in the Middle East.” R...
Poland’s state-run fertilizer producer has temporarily stopped taking new orders as tensions soar in the Middle East and the price of gas, a key input, surges. Grupa Azoty SA will continue production, and the decision applies only to new March orders for nitrogen fertilizers, the company said in a statement. “The reason for the decision is the unstable geopolitical situation in the Middle East.” Read More: Iran War Snarls Key Global Hub for Fertilizer Supplies Azoty is the second-largest producer of nitrogen and compound fertilizers in the European Union, and its decision raises concerns about other firms following suit. The war in Iran is already disrupting flows from the Persian Gulf, a crucial shipping and production hub for fertilizers, pushing up prices at a time when farmers in the Northern Hemisphere prepare to apply the products to their fields. Meanwhile, soaring gas costs will also impact producers of crop nutrients elsewhere, further boosting costs . “Accepting orders on the existing terms and conditions with such a drastic increase in costs would expose the company to negative consequences,” the statement added. Unlike some of its peers, Azoty has chosen not to make its products more expensive for now. Fertilizer producers outside Europe — in Egypt, Algeria, China and the US — decided to immediately raise prices by $45-$70 a ton, Azoty said. “We decided not to pass on such high costs to our partners.” Read More: European Gas Hits Three-Year High as Qatar LNG Halt Rocks Market Grupa Azoty was already facing fierce competition from Russia and Belarus. Last month, it filed a restructuring plan as it sought to settle about 17% of the debt taken on to build the biggest propylene and polypropylene complex in central and eastern Europe. Shares in Azoty slumped nearly 4% in intraday trading in Warsaw.
If POTUS can really bomb peace, stability and women’s rights into the Middle East, I’ll take my hat off to him. Judging by his role in Gaza, I won’t hold my breath Donald Trump says Keir Starmer has damaged the special relationship by not helping him more in the US-Israel war on Iran. But you have to remember that when you do help, Trump pretends you didn’t anyway, and also pisses on your war dead...
If POTUS can really bomb peace, stability and women’s rights into the Middle East, I’ll take my hat off to him. Judging by his role in Gaza, I won’t hold my breath Donald Trump says Keir Starmer has damaged the special relationship by not helping him more in the US-Israel war on Iran. But you have to remember that when you do help, Trump pretends you didn’t anyway, and also pisses on your war dead . Still, what could be more enticing than the Americans trying to sell you a timeshare on a war in the Middle East? And so to Iran. “War is the realm of uncertainty,” said Carl von Clausewitz, who – and not to be a bitch – I still think of as a more impressive military theorist than Pete Hegseth. Certainly, Carl had fewer Crusades tattoos than the US defence secretary. Hegseth is 100% certain about all his nailed-down positions, even the ones in apparent conflict with each other. And it feels like a great sign that he, Marco Rubio and JD Vance already seem to have different rationales for why this war was launched. This is an administration that came to power on an explicit “no more wars” ticket – but look, as Pete keeps saying, this isn’t a regime-change war. If that seems confusing, given he first said it about 10 minutes after US-Israeli strikes had just cratered the ayatollah’s compound, Hegseth has since been on hand to scoff that what’s going down in Iran is “no nation-building quagmire, no democracy-building exercise” . Marina Hyde is a Guardian columnist Continue reading...
cacaroot/iStock via Getty Images Market Overview Global markets in the fourth quarter were shaped by the interplay of central bank policy, shifting rate expectations, and recurring geopolitical and trade-related headlines. The Federal Reserve lowered rates at its final meeting of the year, but investors continued to debate how quickly additional easing might unfold as growth signals stayed resilie...
cacaroot/iStock via Getty Images Market Overview Global markets in the fourth quarter were shaped by the interplay of central bank policy, shifting rate expectations, and recurring geopolitical and trade-related headlines. The Federal Reserve lowered rates at its final meeting of the year, but investors continued to debate how quickly additional easing might unfold as growth signals stayed resilient and inflation readings were interpreted through the lens of data disruptions tied to the government shutdown. Equity markets advanced in a more selective fashion, with ongoing enthusiasm around AI-related investment alongside periodic rotations that favored smaller-cap and value segments at times versus the most crowded mega-cap areas. Outside the U.S., a weaker dollar and relatively more attractive valuations supported international equities; within that, emerging markets also posted gains but tended to trail developed markets modestly, with dispersion across countries and style factors remaining an important driver of results. Meanwhile, intermittent tariff developments and geopolitical risks—including renewed tensions in the Middle East and Venezuela—contributed to bouts of volatility that influenced energy pricing and reinforced demand for perceived safe havens such as gold. Performance Summary Hartford Conservative Allocation Fund (I share) underperformed its benchmark during the period. The main driver of the fund's underperformance versus the benchmark was performance of the underlying positions relative to their individual benchmarks. In particular, Hartford World Bond Fund, Hartford Strategic Income ETF and Hartford Core Equity Fund underperformed their respective benchmarks. Asset allocation decisions did not materially impact performance during the period. Positioning & Outlook Our stance remains overweight equities and underweight fixed income, with balanced regional and style exposure. We expect lower US interest rates and increased government spending in Eu...
(RTTNews) - Byrna Technologies Inc. (BYRN), a defense technology company, announced Tuesday that Bryan Ganz is retiring as Chief Executive Officer and as a member of the Company's Board of Directors. Ganz has been CEO since 2019 after first joining the Company's Board in 2016. Following an extensive search process, with the assistance of a leading independent search firm, the Byrna Board has appoi...
(RTTNews) - Byrna Technologies Inc. (BYRN), a defense technology company, announced Tuesday that Bryan Ganz is retiring as Chief Executive Officer and as a member of the Company's Board of Directors. Ganz has been CEO since 2019 after first joining the Company's Board in 2016. Following an extensive search process, with the assistance of a leading independent search firm, the Byrna Board has appointed Conn Davis to succeed Ganz and join the Board as a Director, effective immediately. To facilitate a smooth transition, Ganz will serve as an advisor to support the incoming CEO for up to six months. Additionally, as part of Byrna's broader leadership succession strategy, TJ Kennedy, who has served as a Director since September 2025, has been elected to succeed Herbert Hughes as Chair of the Board. Hughes will continue to serve as a Director on the Board. Davis most recently served in a series of executive leadership positions at MasterBrand, Inc., culminating in his role as Executive Vice President, Strategy and Corporate Development. Earlier in his time at MasterBrand, Davis served as EVP, Corporate Strategy and GM eCommerce, after serving as Vice President, Corporate Strategy. Prior to joining MasterBrand, Davis served as Director of Strategy at Fortune Brands Home & Security, before which he worked at Bain & Company and at Jenkins & Kling, P.C. and Brown & James, P.C. as an attorney. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Md Saiful Islam Khan/iStock via Getty Images Thesis Arcus Biosciences ( RCUS ) managed to post a 4Q25 GAAP EPS of -$0.89, a figure that beat consensus estimates by about $0.14. We saw some better-than-expected cost control and decent collaboration revenue throughout the quarter. The company also posted a revenue figure of $33 million, down just 8.3% year over year but still beating expectations by...
Md Saiful Islam Khan/iStock via Getty Images Thesis Arcus Biosciences ( RCUS ) managed to post a 4Q25 GAAP EPS of -$0.89, a figure that beat consensus estimates by about $0.14. We saw some better-than-expected cost control and decent collaboration revenue throughout the quarter. The company also posted a revenue figure of $33 million, down just 8.3% year over year but still beating expectations by $8.06 million. This was driven mainly by partnership-related payments. But overall, the quarter showed us pretty solid earnings and revenue beat despite Arcus still going through a heavy investment phase with no commercial products yet. Arcus now has a pretty busy 2026, with most of the spending going towards Casdatifan, a next-generation, orally administered small-molecule inhibitor of hypoxia-inducible factor-2 alpha. So far, we have seen a whole host of positive data, which is largely why the stock price has run up so much across 2025. Much of the upside ahead and future revenue would be dependent on the candidate, so it's worth looking into what we've seen so far and what we need to see for upcoming trials to justify a valuation profile, which is now screening as a bit expensive. Arcus Biosciences FY25 financial results Arcus just closed out a pretty strong FY25 . We also saw a very decent balance sheet for a clinical-stage biotech, with about $1.01 billion in cash, cash equivalents, and marketable securities, up slightly from $992 million at the end of FY24. Now, the jump in cash was mainly driven by about $429 million in equity financing, a $50 million drawdown on its term loan facility, and $37 million in milestone and option payments from Taiho. All this more than offset their elevated R&D spending. Management also expects that cash position to fund operations into at least 2H28, which is a major positive for investors given the multiple Phase 3 programs they have going on. Arcus Biosciences, Inc. As for revenue, FY25 saw about $247 million, down only slightly from...
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +13.39%. A quarter ago, it was expected that this company would post a loss of $0.28 per share when it...
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +13.39%. A quarter ago, it was expected that this company would post a loss of $0.28 per share when it actually produced a loss of $0.32, delivering a surprise of -14.29%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Prime Medicine, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.84 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 63.64%. This compares to year-ago revenues of $2.18 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Prime Medicine, Inc. shares have added about 34.3% since the beginning of the year versus the S&P 500's gain of 0.5%. What's Next for Prime Medicine, Inc.? While Prime Medicine, Inc. has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing ...